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CD4+CD25+REGULATORY T CELLS AND THEIR ROLE IN SYSTEMIC
LUPUS ERYTHEMATOSUS
Sara Shilcrat
INTRODUCTION
Systemic lupus erythematosus, or SLE, is an autoimmune disease that currently has no
known cause or cure (Postal et al. 2012; Okamoto et al. 2011). According to the Lupus
Foundation of America, 1.5 million Americans are thought to be suffering from SLE. It is found
in females ages 15-44 but may also been seen in men, teens, and children (Lupus Foundation of
America 2012). It is characterized by the loss of the immune system’s ability to discern between
“self” and foreign antigens. This leads to autoantibody production, abundant production of
proinflammatory cytokines, stimulation of complement, and “immune complex depositions”
(Okamoto et al. 2011). Multiple organs and tissues are affected due to the dysfunction of the
immune system. Patients with SLE show an increased mortality rate compared to the population
at large (Okamoto et al. 2011), although the five year survival rate is currently at 90% (Postal et
al. 2012). The disease displays periods of advancement, remission achieved through drug
therapy, and relapses. Genetic, hormonal, and environmental factors are thought to interact in the
initial development of the disease, which can manifest itself in a variety of ways. Current
treatment options include corticosteroids and immunosuppressants, which have resulted in some
toxic effects in clinical use. To find a cure for SLE and improve patient prognoses, it is necessary
to better understand the pathology behind the disease in order to formulate new drug therapies
(Okamoto et al. 2011; Postal et al. 2012).
During the formation of T cells, autoreactive T cells, or T cells that target the body’s own
tissues as opposed to foreign antigens, are generally prevented from maturing and entering into
circulating T cell defenses. However, at times, autoreactive T cells developing in the thymus
may slip past the body’s checks and enter into the circulation. Recent research has found that it is
the job of regulatory T cells, or Tregs, to prevent these cells from attacking body tissues, a
function known as peripheral tolerance (Okamoto et al. 2011; Venigalla et al. 2008). In effect,
the Tregs are aptly called the “mediators of peripheral tolerance and potent suppressors of
excessive immune responses” (Okamoto et al. 2011). More knowledge is needed to find out
about these Tregs, how they function to prevent autoreactive attacks by responder T cells, and
how they mediate cytokine production. A specific group of Tregs, namely the CD4+ CD25+
Tregs, has been avidly studied for their role in peripheral tolerance and autoimmune diseases like
SLE. Understanding how these Tregs function, or sometimes fail to function properly, will allow
for breakthroughs in SLE treatments and patient prognoses and is the impetus for this literature
review (Okamoto et al. 2011).
The experiments discussed here include studies done on amounts and percentages of
Tregs in SLE patients’ peripheral blood compared to healthy controls (Baráth et al. 2007), how
the number of Tregs affects the activity of the disease (Baráth et al. 2007), the lack of
suppression by Tregs over responder T cells and responder T cells’ cytokine production,
including TNF-α and IFN-γ, in the blood and skin lesions of SLE patients (Carneiro et al. 2008;
Valencia et al. 2007; Venigalla et al. 2008), and finally, the effects of rituximab treatment on the
ratio of Th1/Th2 CD4+ T cells (Tamimoto et al. 2008). These experiments give a broad
understanding of how the amounts of Treg cells differ between healthy controls and SLE patients
and how the Tregs display altered suppressive functioning in SLE patients leading to an
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improved understanding of the course of the disease and possible routes for new treatment
options.

DISCUSSION
Amounts and percentages of Tregs in SLE patients’ peripheral blood
Multiple studies have been conducted to determine the amounts of Tregs cells in SLE
patients with differing results (Crispin et al. 2003, Liu et al. 2003, Fathy et al. 2005, AlvaradoSanchez et al. 2006, Miyara et al. 2005 cited in Venigalla et al. 2008). Baráth et al. did a study
using flow cytometry that matched results from prior studies (Crispin et al. 2003, Liu et al. 2003
cited in Baráth et al. 2007) showing that the percentage of CD4+CD25+FoxP3+ Tregs was
decreased in SLE patients compared to controls (in percentage per liter of peripheral blood;
controls: 4.55%, n=32; SLE patients: 3.21%, n=44) as well as the numbers of Treg cells
(controls: 0.038±0.017 G/L; SLE patients: 0.012±0.006 G/L).
Correlation between disease activity and amount of Tregs after plasmapheresis treatment
Five patients suffering from advanced forms of SLE that were not responding to
conventional treatments were subjected to repetitive plasmapheresis treatments to determine the
treatments’ effects on counts of Treg cells (CD4+ CD25+ FoxP3+ T cells). An inverse
correlation was seen between the SLEDAI, or disease activity, and the number of Treg cells,
with the disease regressing and the number of Treg cells increasing (r=-0.96, r2=0.92, P=0.008)
(Baráth et al. 2007).
Treg functioning in the suppression of responder T cells and cytokine production
In one study, responder T cells (Tresp) of active1 SLE patients were found resistant to the
regulatory effects of CD4+ CD25high CD127-/low regulatory T cells (Tregs) that suppress their
proliferation (Venigalla et al. 2008). The researchers built their study off of past research
(Crispin et al. 2003; Liu et al. 2003; Fathy et al. 2005; Alvarado-Sanchez et al. 2006; Miyara et
al. 2005) that differed as to whether SLE patients displayed differences in the percentage or
overall amount of Treg cells. The researchers attributed the differences in the results to the lack
of proper purification of the CD4+ CD25high Treg cells. SLE patients are known to have an
abundance of an effector T cell called CD4+ CD25++ that is similar to the CD4+ CD25 high Treg
cells. These similar CD4+ CD25++ T cells cause contamination of counts that are meant to
quantify CD4+ CD25high Treg cells. A culture of CD4+ CD25high Treg cells that shows
proliferation is thought to be contaminated with the CD4+ CD25++ effector T cells since CD4+
CD25high Treg cells do not proliferate (Venigalla et al. 2008).
Procedure for procuring pure Treg samples
To alleviate the contamination problem, the researchers used a simultaneous staining
procedure that targeted two T cell antigens: the CD25 and CD127 antigens. The researchers
based their procedure on findings that indicated that the antigen CD127 allows for effective
sorting between effector and regulatory T-cells; effector T cells express this antigen, or are
known as CD127+, while regulatory T cells show little to no expression of this antigen, CD127/low
(Liu et al. 2006, Seddiki et al. 2006, Hartigan-O’Connor et al. 2007 cited in Venigalla et al.
2008).
The authors proved that past research that aggregated ‘Treg cells’ by selecting for CD4+
CD25high T cells via flow cytometry used contaminated cultures that contained more than just
Treg cells. By testing the proliferation of cells characterized as CD4+ CD25 high versus cells with
CD4+ CD25high and the additional CD127-/low parameter, results showed significantly fewer of
1

Active refers to the disease in a state of advancement while inactive refers to the disease being in a remission state
(Valencia et al. 2007; Venigalla et al. 2008).
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the latter type of cells. Solidifying the results further, the percentage drop in proliferation seen
between the CD4+ CD25high ‘Treg cells’ and the highly purified CD4+ CD25high CD127-/low
Tregs cells of SLE patients (P =0.0003) approached the percentage drop seen between these two
types of cells in healthy controls (P=0.004) (Venigalla et al. 2008).
For further verification that the cells collected from the purification procedure were
actual Tregs, the researchers compared the amounts of CD4+ CD25 high CD127-/low Treg cells to
counts done of verified regulatory T cells, or CD4+ CD25 high FoxP3+ Treg cells. FoxP3, or
forkhead box P3, is a transcription factor that is critical for normal Treg cell development
(Fontenot et al. 2003 cited in Venigalla et al. 2008). The researchers could not use the FoxP3
transcription factor as a limiter for isolating true Treg cells with flow cytometry (instead of
antigen CD127) due to the fact that FoxP3 is an intracellular marker. However, counts of Treg
cells with FoxP3 (or FoxP3+) were done as a check to compare to amounts of CD127 -/low Treg
cells collected. If the values between the two types of cells showed a significant positive
correlation, it could be concluded that the CD4+ CD25 high CD127-/low T cells were the true Treg
cells. When comparing the purification results of the CD4+ CD25 high CD127-/low Treg cells to the
CD4+ CD25high FoxP3+ Treg cells, a high positive correlation was seen between the total
amount of each type of cell both for the SLE patients (r 2 = 0.77, P=0.0009, n = 13) and for the
normal controls (r2 = 0.70, P˂0.0001, n = 17), proving the likelihood that the CD127 -/low cells
were indeed classic Treg cells (Venigalla et al. 2008).
Use of CD4+ CD25+ FoxP3+ Treg cells from control and SLE patients, both active and
inactive cases, also highlighted that active SLE patients had an increase in the average
percentage of CD4+ CD25low FoxP3+ T cells and CD4+ CD25high FoxP3+ T cells compared to
healthy controls and patients with inactive SLE. Both types of cells, however, did not show
significantly increased amounts when measured in comparison to a set volume of peripheral
blood mononuclear cells (Venigalla et al. 2008).
Effects of Tregs on Tresp cells in SLE patients
After procuring pure samples of the Treg cells (CD4+ CD25 high CD127-/low), the
researchers determined the effects of CD4+ CD25 high CD127-/low Treg cells on T cell responders
(Tresp). The researchers cultured measured amounts of the Treg cells with the Tresp cells.
Different ratios of cells were created (Treg:Tresp), spanning from 1:1 to 0.03125:1 ratios.
Results of the experiment from the 1:1 ratio of control Treg cells to control Tresp cells showed
an 80±2% (n=9) inhibition of proliferation of the Tresp cells. With the decreasing amount of
control Treg cells compared to the set value of control Tresp cells, the percentage of inhibition
gradually decreased. On the other hand, the experimental group consisting of participants with
active SLE showed decreased Treg-related suppressive functioning, with baseline inhibition of
Tresp proliferation at a 1:1 ratio of only 53±6% (n=9). This statistically significant decrease in
inhibition of proliferation ranged from the 1:1 ratio down until the 0.125:1 ratio (P=0.0006).
Similar findings to a lesser extent were found when controls were compared to patients with
inactive SLE (88±1% (n=8) versus 77±2% (n=8), ratios from 1:1 down until 0.25:1, P=0.0006)
(Venigalla et al. 2008).
Responder T cells of SLE patients were not sensitive to the regulation of the Treg cells;
two opposing hypotheses were conjectured to understand where the decreased sensitivity to the
Treg cells stemmed from. The first hypothesis ascertained that the Treg cells in SLE patients
were dysfunctional and lacked the ability to suppress the Tresp cells. Conversely, the second
hypothesis implicated that the Tresp cells became resistant to the signals sent by the Treg cells
and proliferated of their own accord. To test these two opposing theories, Tresp cells of active
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SLE patients were grown with control Treg cells and vice versa. Tresp cells of active SLE
patients cultured with control Tregs allowed for the following conclusions; if the suppression of
the propagation of Tresp occurred by the control Treg cells at the elevated rate (around 80%), the
problem could be isolated to the malfunctioning of the SLE patients’ Treg cells. If, however, the
suppression remained at the same level as that seen normally in active SLE patients, the SLE
patients’ Tresp cells were thought to have become immune to the mediation of SLE Treg cells.
When testing the reverse (culturing Tresp cells of controls with Treg cells of active SLE
patients), if the inhibition of the proliferative effects of the Tresp was very high as in the control
patients, then the Tresp cells of the SLE patients’ were thought to be resistant to SLE Treg cells.
Just the opposite, if the reduction in Tresp proliferation was lower as in the active SLE patients,
then the Tregs of the SLE patients were thought to have lost their mediating capacity. In the first
case (control Treg cells + active SLE Tresp), the control Treg cells were unable to suppress the
proliferation of the Tresp cells of the SLE patients, implicating a problem with the Tresp
(74±5%, n=15 for control Treg cell/control Tresp cells vs. 48±6%, n=15 for control Treg
cells/active SLE Tresp cells; P=0.001). The results were further confirmed to be related to the
development of resistance by the active SLE patients’ Tresp cells in the second experiment
(active SLE Treg cells + control Tresp cells) where the active SLE Treg cells could suppress the
control Tresp cells (48±6%, n=15 active SLE Treg cells/active SLE Tresp cells vs. 63±6%, n=15
active SLE Treg cells/control Tresp cells; P=0.03) (Venigalla et al. 2008).
From the testing, the Tresp cells were found to be resistant to the mediation of the Treg
cells in active SLE patients. Other testing was conducted that further solidified the view that the
Tresp were indeed not responsive to the Treg inhibition in active SLE patients. Statistically, the
degree of inhibition of Tresp cell proliferation was inversely proportional to the level of activity
seen in the disease, or more diseased states showed a decrease in the ability of the Treg cells to
control the Tresp proliferation (r2 = 0.37, P˂0.0001, n=28). Finally, the researchers used ELISA
during the assay on the control and active SLE T cells that showed the production of interferongamma (IFN-γ), a Th1 class of cytokines produced by Tresp cells and regulated by Treg cells,
with the following results:
Treg cells of: IFN-γ production by:

Able to suppress IFN-γ production?

Control

Control Tresp cell

Yes

Control

Active SLE Tresp cell

No (not as well suppressed)

Active SLE

Active SLE Tresp cell

No (unable to suppress)

Active SLE

Control Tresp cell

Yes

These results further prove the lack of Tresp cells of active SLE patients to respond to
Treg cell mediation, whether it is the cell directly (i.e. via proliferation) or the products that the
cell makes (i.e. IFN-γ production). An interesting supposition that the authors mention is the
possibility that cytokines, like IFN-γ, may initiate the active SLE patients’ Tresp cells to
‘retaliate’ and build resistance to the regulation of the Treg cells. To determine the voracity of
this hypothesis, the role of the cytokines must be determined (Venigalla et al. 2008).
Contradictory research proving Tregs are malfunctioning. CD4+ CD25 high Treg cells help
in the maintenance of “immunologic homeostasis” and prevention of autoimmunity (Valencia et
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al. 2007). Deficient Tregs, like those seen in SLE, attack target cells, increase cytokine
production, increase cell-to-cell contact, and lead to apoptosis of target cells. In another study on
Tregs (Valencia et al. 2007), the researchers hypothesized that the characteristic breakdown of
“self” tolerance in SLE patients was due to altered Treg functioning. Findings from their
research were in line with their hypothesis. Active SLE Tregs showed a decrease in FoxP3
mRNA and protein expression compared to controls and inactive SLE participants (controls:
mean 85±5%, n=40; inactive SLE: mean 64.4±15%, n=8; active SLE: mean 45±10%, n=10
[P=0.003 comparison between controls and active SLE; P=0.2 comparison between inactive SLE
and controls]). Decreases in this gene expression were not mentioned in Venigalla and
colleagues’ experiment (2008). Differing from results seen with Venigalla et al. (2008), Tregs
were implicated as malfunctioning, doing a poor job of inhibiting the proliferation of CD4+
CD25- T responder (Tresp) cells and their cytokine secretions. The significant decrease that was
evident in the suppressive functioning of the CD4+ CD25 high Treg cells from the active SLE
patients extended to both Tresp from controls and “self” (active SLE) Tresp cells. Further
supporting the premise that the Tregs were defective, the problem could not be contributed to
resistance conferred on the Tresp cells (like the findings of Vanigella et al. in 2008), as Tregs
from the controls were able to suppress active SLE Tresp cell proliferation. With respect to
inactive SLE patients, their Tregs were markedly different from those of the active SLE patients,
displaying similar suppressive capabilities as control Tregs (Valencia et al. 2007).
Reversible loss of Treg suppressive functioning
The researchers also found that the loss of suppressive abilities of the active SLE Tregs
could be reversed, not studied in the subsequent experiment done by Venigalla et al. in 2008.
Incubating the Tregs in vitro with anti-CD3 led to activation of the Tregs. As a result, the Tregs
exhibited an increase in FoxP3 mRNA and protein expression and restoration of their
suppressive functioning on Tresp cell proliferation and IFN-γ secretion (Valencia et al. 2007).
Phenotypic changes in Tregs of SLE patients. Valencia et al. (2007) also studied the
phenotype of the Treg cells harvested from controls and SLE patients. The Treg cells from active
SLE patients differed phenotypically from Tregs collected from controls and inactive SLE
patients. In particular, TNFRII, which has been linked to another autoimmune disease (Valencia
et al. 2006 cited in Valencia et al. 2007), was increasingly expressed. TNFRII is part of a
signaling pathway that downregulates CD4+ CD25 high Tregs’ suppressive function on CD4+
CD25- Tresp cells. Since active SLE Treg cells displayed an inability to regulate Tresp
proliferation, the researchers tested whether TNF moderated the suppressive capacity active SLE
Tregs. Results from the experiment displayed that adding anti-TNFRII antibodies or TNF
stopped control and anti-CD3 activated active SLE Tregs from being able to inhibit CD4+
CD25- Tresp cells. The cells lost their regulatory capacity, indicating that expression of TNFRII
affects the Tregs ability to contain Tresp multiplication (Valencia et al. 2007).
Correlations between SLE disease activity and Treg phenotype and suppressive capacity
Two notable inverse correlations were discovered in this study. The first correlation was
found between SLE Treg FoxP3 expression and SLEDAI score, the systemic lupus
erythematosus activity score2. Interpreting the correlations, a patient with a more active form of
the disease had decreased FoxP3 expression and vice versa. A second inverse correlation was
found between the percentage of suppression that the Tregs exhibited over the Tresp and the
SLEDAI score. A patient with a more active form of the disease displayed Tregs with a lessened
2

To be classified as an inactive SLE patient, the SLEDAI score needed to be less than 3, while an active SLE
patient scored at or above 3 (Valencia et al. 2007).
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capacity for suppressing the proliferation of their Tresp cells. Interestingly, no correlation existed
between therapeutic drugs (glucocorticoids) and Treg functioning, indicating that malfunctioning
of the Tregs was not related to the therapeutic treatment (Valencia et al. 2007).
Treg suppressive functioning and cytokine secretions in SLE patients’ skin lesions. It is
evident that proper control over Tresp and their cytokine secretions is lacking in SLE patients,
whether it is due to the malfunctioning of the Tregs or the resistance of the Tresp to the Tregs’
regulation. Cytokine secretions are increased, such as TNF-α and IFN-γ, due to the lack of
regulation over the Tresp that produce these two cytokines.
Imminunologic disorders in several inflammatory diseases have been characterized
according to the dominant cytokine pattern of the infiltrating CD4+ T cells. A Th1 pattern is
characterized by predominance of interleukin-2 (IL-2) and interferon- γ (IFN- γ), whereas a Th2
pattern is characterized by predominance of IL-4, IL-5, IL-6, IL-10, IL-13 (Carneiro et al. 2011).
In a study by Carneiro et al. (2011), the researchers sampled epidermal keratinocytes of
SLE patients extracted from areas of unaffected skin and skin lesions commonly found in SLE
patients (both discoid and acute). Using PCR, the researchers quantified the amounts of 4
cytokines (IFN- γ, IL-2, IL-5, TNF-α) found in the skin cells. The results showed overexpression
of at least one of the four cytokines in 47% of the 38 skin samples. Examining IFN- γ in
particular (which is produced by the Tresp cells), 8 out of the 38 biopsies taken showed
overexpression of this cytokine (7/8 of the biopsies were from acute/discoid lesions while the 8 th
came from an unaffected area of skin). TNF-α was overexpressed in only 3 samples taken from
areas with skin lesions. From the results showing overexpression of IFN- γ specifically, the
authors indicated that this suggests that Th1 class of CD4+ T cells, related to Treg cells and their
functioning, may play some role in SLE’s skin-related pathology (Carneiro et al. 2011).
Effects of rituximab on the ratio of Th1/Th2 CD4+ T cells
One drug on the market for SLE that was created to target B cells called rituximab has
shown an effect on the ratio of Th1/Th2 CD4+ T cells (Postal et al. 2012). Rituximab has a
tendency to tip the ratio in favor of Th1 CD4+ T cells over Th2 CD4+ T cells and may yield
these effects by decreasing serum levels of TNF-α 3 (Tamimoto et al. 2008), mentioned
previously with regard to the ability of this cytokine to inhibit Tregs’ suppressive capacity over
Tresp cells (Valencia et al. 2007). The study of rituximab, showed its safety, but more
importantly, the drug generated remission in approximately 89% percent of the patients (n=9).
Improvement in SLE patients leading to remission is, therefore, linked to changes in T cells and
cytokine secretions (Tamimoto et al. 2008).

CONCLUSION
Treg cells are an important area of research in helping treat SLE patients. SLE patients
suffer from having fewer of these important regulatory T cells, which help prevent
autoimmunity. Other concerns include the changes in the phenotype of the remaining Treg cells
and the production of TNF affecting the suppressive capacity of Tregs over Tresp (Valencia et al.
2007).
However, it is encouraging that plasmapheresis treatments in patients not responding to
conventional SLE treatment showed increases in their Treg counts and decreases in their
SLEDAIs, or disease activity (Baráth et al. 2007). Another promising finding is the similarity
between inactive SLE patients and healthy controls with regard to appropriate Treg functioning
3

The ratio for Th1/Th2 CD4+ T cells was calculated from flow cytometry of the CD4+ T cells. Th1 cells were
determined as the percentage of IFN-γ+ cells while Th2 cells were determined as interleukin-4 positive, or IL-4+
cells (Tamimoto et al. 2008).
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(Valencia et al. 2007). This indicates that patients in remission, which could be brought about by
use of rituximab (Tamimoto et al. 2008), may generate restored Treg functioning. It is also
interesting to hypothesize whether activation of Tregs, ex or in vivo, can be used clinically to
restore proper Treg functioning in SLE patients like the in vitro findings seen in Valencia et al.’s
experiment in 2007.
Review of this research is important for clarifying how Treg cells in particular relate to
the current knowledge of SLE pathology and bring the researchers closer to finding which
mechanism can be targeted as a cure for this disease. From the research presented, it is evident
that impairment of proper Treg functioning, whether on the part of the Tregs or the Tresps, leads
to the detrimental proliferation of Tresp cells and their respective cytokines that is characteristic
of the autoimmune disease. It is necessary to conduct more research to determine whether Tregs
or Tresps are malfunctioning, as the research differed on this point. Determination of the source
of increased Tresp cells and cytokine production will allow for the creation of treatment options
that target the deficient cells.
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